Loading
RNA Interference and Gene Delivery / CRISPR and Genetic Engineering · Journal article
Molecular Medicine · September 9, 2026
A consensus or society position rather than new primary data.
This is a narrative review synthesizing contemporary advances in CRISPR delivery systems, identifying cellular and tissue delivery as the primary clinical bottleneck, and cataloguing viral and non-viral vector strategies under investigation. The work does not report original data or comparative outcomes, but rather organizes the field's current understanding across in vitro, ex vivo, and in vivo contexts.
Narrative review. CRISPR-based therapeutics in development; no specific patient or cell population studied..
Delivery of CRISPR machinery to designated tissues constitutes the primary bottleneck in clinical translation. Biological impediments include rapid clearance, limited tissue penetration, endosomal entrapment, and adaptive immune responses. Contemporary delivery approaches include viral vectors, non-viral nanoparticle systems, physical methods, and peptide/protein-mediated platforms.
No primary efficacy or safety data reported; abstract does not state which delivery strategies are most advanced or clinically promising.
Clinicians and researchers should recognize that delivery, not nuclease activity or targeting, remains the rate-limiting step in translating CRISPR to clinical use. This review provides a framework for understanding the landscape of vectors and strategies currently being pursued, but does not report efficacy or safety data to guide treatment selection.
A narrative review synthesizing recent advances in CRISPR delivery strategies across research and clinical contexts, offering state-of-the-art overview rather than novel empirical evidence or recommendations.
As stated by the source record.
Clinicians and researchers should recognize that delivery, not nuclease activity or targeting, remains the rate-limiting step in translating CRISPR to clinical use. This review provides a framework for understanding the landscape of vectors and strategies currently being pursued, but does not report efficacy or safety data to guide treatment selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract The rapid development of CRISPR genome editing technologies has established a transformative paradigm within biomedical research, drug discovery, and gene therapy. Despite the robust nuclease activity and programmable targeting exhibited by these systems, the clinical translation of CRISPR-mediated therapeutics remains substantially impeded by systemic and cellular delivery constraints. Specifically, the secure, highly efficient, and spatiotemporally controlled administration of CRISPR machinery to designated tissues or distinct cell populations constitutes the primary bottleneck in the field. Physiological and biological impediments, including rapid clearance, limited tissue penetration, endosomal entrapment, and potential adaptive immune responses, necessitate the development of highly specialized delivery vectors to ensure therapeutic viability and mitigate off-target effects. To circumvent these biological barriers, contemporary research has extensively evaluated a spectrum of delivery vehicles engineered to package and protect diverse CRISPR cargoes, including DNA, RNA, and pre-assembled ribonucleoprotein complexes. These diverse cargos are actively investigated in conjunction with established viral vectors, and an expanding array of non-viral vectors encompassing physical methods, nanoparticle‑based systems, and peptide/protein‑mediated platforms. This review delineates the recent advancements in discovery of CRISPR‑based genome editing tools, with a particular emphasis on delivery strategies across in vitro modeling, ex vivo cellular engineering, and in vivo clinical interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.